This Expert Perspective highlights the salient points of the joint Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), published in 2012, on the management of hyperglycemia in type 2 diabetes.
The aim of this program is to examine the cardiovascular effects of pharmacotherapies used in managing type 2 diabetes with a focus on key clinical trials regarding the use of diabetes medications in patients with established or at elevated risk for cardiovascular disease.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and basal insulin analogs are essential antihyperglycemic therapies for many patients with type 2 diabetes mellitus (T2DM) (eg, those in need of large glucose-lowering effects or, based on recent updates to the official indications for 2 of the GLP-1 RAs). This Engaging the Patient activity will discuss newer insulin therapies as well as GLP-1 injectable therapies, including rationales and clinical trial evidence for combining these two agents. The activity includes a demonstration of clinician and patient interactions-ways to educate patients on the use of injectable medications, as well as approaches to reducing hypoglycemia and improving patient adherence.
This activity is part of the ConnectED Learning: Diabetes curriculum. Join expert faculty as they address your remaining questions and provide a distillation of clinical pearls from the ConnectED Learning Curriculum on the management of diabetes
This activity is part of the ConnectED Learning: Diabetes curriculum. In this Expert Perspective, Dr. Richard Pratley outlines the main facets of utilizing oral combination therapy to intensify treatment in order to achieve HbA1c goals while minimizing side effects and cardiovascular risk.
This activity is part of the ConnectED Learning: Diabetes curriculum. It is well proven that effective glycemic control among patients with type 2 diabetes can reduce the risk of diabetes-related microvascular and macrovascular complications. This dynamic live educational program will feature renowned faculty experts who will lead an interactive discussion on important evidence supporting emerging clinical strategies, shared decision making, and ways in which to individualize care to best manage the complex challenges of diabetes and the progression of disease. It will include therapeutic approaches that can reduce the risks such as hypoglycemia, weight gain, and cardiovascular events.
Dr. de la Cruz-Muñoz, an expert in laparoendoscopic and bariatric surgery, will review evidence regarding the treatment of obese patients with uncontrolled type 2 diabetes with bariatric surgery.
There are several challenges in the management of T2DM that faces clinicians today in the real-world setting. This case study is designed to improve clinician competence and practice.
The aim of this program is to examine the science of cardiometabolic disease and assess the risks and benefits of cardiovascular risk reduction strategies, with a special focus on women, the elderly, and chronic kidney disease.
The talk focuses on the evidence for short- and long-term benefits of achieving and maintaining glycemic control in patients with T2D, and discusses options for lifestyle and medication management to achieve such control. Randomized controlled trials that will provide new information about optimal management approaches, such as the NIH's GRADE trial, will be discussed. In particular, the results of recent Cardiovascular Outcomes Trials for newer diabetes medications highlight the importance of CV prevention in patients with T2DM.
The T2DM treatment paradigm has shifted significantly over the past few years with the emergence of new therapies designed to better address underlying pathophysiologic defects, while reducing untoward events and improving health outcomes. This rich array of emerging therapeutic options, alongside existing treatment approaches, can become overwhelming and potentially confusing as we look for the best clinical strategies to meet our patients’ needs. In this webcast, leading experts will discuss the latest evidence-based guideline recommendations for management of T2DM across the continuum of care, while lending practical insights on how to best tailor treatment based on a patient’s individual clinical presentation, risks, and needs. Discussion will focus on distinguishing new and emerging non-insulin therapies, including GLP-1 receptor agonists, in order to improve glycemic control, overcome clinical challenges, and mitigate cardiometabolic risks.